Delving into the Latest Updates on BeiGene (Suzhou) Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Immune System Diseases

Small molecule drug

Proteolysis-targeting chimeras (PROTAC)

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	12
Immune System Diseases	9
Hemic and Lymphatic Diseases	7
Endocrinology and Metabolic Disease	3
Nervous System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	9
Proteolysis-targeting chimeras (PROTAC)	2
Bispecific antibody	1
Monoclonal antibody	1
Chemical drugs	1

Top 5 Target	Count

BTK(Tyrosine-protein kinase BTK)	2
Bcl-2(Apoptosis regulator Bcl-2)	2
PD-1(Programmed cell death protein 1)	1
IRAK4(Interleukin-1 receptor-associated kinase 4)	1
PRMT5(Protein arginine methyltransferase 5)	1

一项评价BGB-11417单药、BGB-11417联合地塞米松与BGB-11417联合地塞米松和卡非佐米、地塞米松和达雷妥尤单抗以及地塞米松和泊马度胺治疗携带t(11;14)的复发/难治性多发性骨髓瘤患者的安全性和有效性的1b/2期、剂量递增和队列扩展研究

[Translation] A Phase 1b/2, dose-escalation, and cohort expansion study evaluating the safety and efficacy of BGB-11417 alone, BGB-11417 plus dexamethasone, BGB-11417 plus dexamethasone and carfilzomib, dexamethasone and daratumumab, and dexamethasone and pomalidomide in patients with relapsed/refractory multiple myeloma harboring t(11;14)

第一部分主要目的：评价Sonrotoclax联合地塞米松与Sonrotoclax联合地塞米松和卡非佐米、地塞米松和达雷妥尤单抗以及地塞米松和泊马度胺治疗携带t(11;14)的R/R MM患者的安全性和耐受性；确定Sonrotoclax联合地塞米松与Sonrotoclax联合地塞米松和卡非佐米、地塞米松和达雷妥尤单抗以及地塞米松和泊马度胺治疗携带t(11;14)的R/R MM患者的最大耐受剂量（MTD）/最大评估剂量（MAD）和初步2期推荐剂量（RP2D）; 第二部分主要目的：评价在RP2D下Sonrotoclax单药与Sonrotoclax联合地塞米松治疗携带t(11;14)的R/R MM患者的安全性和耐受性；评价Sonrotoclax联合地塞米松和卡非佐米在推荐剂量组合下治疗携带t(11;14)的R/R MM患者的安全性和耐受性；通过总缓解率和其他缓解率指标评估Sonrotoclax单药、Sonrotoclax联合地塞米松、Sonrotoclax联合地塞米松和卡非佐米治疗携带t(11;14)的R/R MM患者的有效性。

[Translation]

The main objectives of the first part: To evaluate the safety and tolerability of Sonrotoclax combined with dexamethasone, Sonrotoclax combined with dexamethasone and carfilzomib, dexamethasone and daratumumab, and dexamethasone and pomalidomide in the treatment of R/R MM patients with t(11;14); To determine the maximum tolerated dose (MTD)/maximum assessed dose (MAD) and preliminary phase 2 recommended dose (RP2D) of Sonrotoclax combined with dexamethasone, Sonrotoclax combined with dexamethasone and carfilzomib, dexamethasone and daratumumab, and dexamethasone and pomalidomide in the treatment of R/R MM patients with t(11;14); The main objectives of the second part: To evaluate Sonrotoclax alone and Sonrotoclax combined with dexamethasone in the treatment of R/R MM patients with t(11;14) under RP2D Safety and tolerability in MM patients; Evaluate the safety and tolerability of Sonrotoclax combined with dexamethasone and carfilzomib in the treatment of R/R MM patients with t(11;14) at the recommended dose combination; Evaluate the efficacy of Sonrotoclax alone, Sonrotoclax combined with dexamethasone, and Sonrotoclax combined with dexamethasone and carfilzomib in the treatment of R/R MM patients with t(11;14) by overall response rate and other response rate indicators.

Start Date27 Dec 2023

Sponsor / Collaborator

BeiGene (Suzhou) Co. Ltd.

CTR20231287 / RecruitingPhase 1

一项Bcl-2抑制剂BGB-21447用于成熟B细胞恶性肿瘤患者的1/1b期、开放性、剂量递增研究（目前开展剂量探索部分）

[Translation] A Phase 1/1b, open-label, dose-escalation study of the Bcl-2 inhibitor BGB-21447 in patients with mature B-cell malignancies (dose-finding portion currently underway)

主要目的: 1.评价BGB-21447单药治疗的安全性和耐受性，并确定BGB-21447单药治疗复发或难治性（R/R）非霍奇金淋巴瘤（NHL）患者的最大耐受剂量（MTD）或最大给药剂量（MAD）以及初步2期推荐剂量（RP2D） 2.在评价的疾病类型中评价递增给药方案的安全性和耐受性次要目的: 评估BGB-21447的药代动力学（PK）特征评估BGB-21447单药治疗的初步抗肿瘤活性

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of BGB-21447 monotherapy and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and preliminary Phase 2 recommended dose (RP2D) of BGB-21447 monotherapy in patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) 2. To evaluate the safety and tolerability of the escalating dosing regimen in the evaluated disease types Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of BGB-21447 To evaluate the preliminary anti-tumor activity of BGB-21447 monotherapy

Start Date27 May 2023

Sponsor / Collaborator

BeiGene (Suzhou) Co. Ltd.

100 Clinical Results associated with BeiGene (Suzhou) Co. Ltd.

Login to view more data

0 Patents (Medical) associated with BeiGene (Suzhou) Co. Ltd.

Login to view more data

100 Deals associated with BeiGene (Suzhou) Co. Ltd.

Login to view more data

100 Translational Medicine associated with BeiGene (Suzhou) Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

3

2

IND Approval

Phase 1 Clinical

5

2

Phase 2 Clinical

Phase 3 Clinical

1

NDA/BLA

Approved

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Pamiparib ( PARP1 x PARP2 )	BRCA-mutated Peritoneal Neoplasms More	Approved
Zanubrutinib ( BTK )	Follicular Lymphoma More	Approved
Zanidatamab ( HER2 )	HER2 positive Biliary Tract Neoplasms More	NDA/BLA
Tislelizumab ( PD-1 )	Hepatocellular Carcinoma More	Phase 3
Sonrotoclax ( Bcl-2 )	Waldenstrom Macroglobulinemia More	Phase 2